Papers/PMID:37333786
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.
The Pan African medical journal2023The record
6 findings drawn from this paper, on 1 compound across 6 endpoints, 5 of them null.
What it reported
How to read these marksWhat moved
1 finding
resveratrol — decreases total testosterone
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.Finding“The pooled effect estimate indicated that resveratrol significantly reduced the level of testosterone, compared with the placebo (SMD = -0.40; 95% CI [-0.71, -0.10], P = 0.009).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 169
- Dose
- 800, 1000 or 1500 mg/day oral resveratrol
- Population
- Women with polycystic ovary syndrome; 3 of 4 pooled RCTs, resveratrol vs placebo
Effect -0.4 standardised mean difference, 95% CI -0.71 to -0.1
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786
What did not
5 findings
resveratrol — no detected effect on total cholesterol (TC)
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“The pooled effect estimate revealed no effect of resveratrol on cholesterol (MD = -5.91; 95% CI [-18.54, 6.72], P = 0.36).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 108
- Dose
- 1000 or 1500 mg/day oral resveratrol
- Population
- Women with polycystic ovary syndrome; 2 pooled RCTs, resveratrol vs placebo
Effect -5.91 mean difference, 95% CI -18.54 to 6.72
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786
resveratrol — no detected effect on clinical pregnancy rate
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“The pooled relative risk (RR) indicated no effect of resveratrol regarding clinical pregnancy rates (RR = 0.89; 95% CI [0.65, 1.23], P = 0.49).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 101
- Population
- Women with PCOS, pooled across 2 RCTs (n=101: 50 resveratrol, 51 placebo).
Effect 0.89 risk ratio, 95% CI 0.65 to 1.23
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786
resveratrol — no detected effect on HDL cholesterol
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull resultreplicated ×1“The pooled effect estimate revealed no effect of resveratrol on HDL (MD = 0.24; 95% CI [-3.53, 4.00], P = 0.90).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 108
- Population
- Women with PCOS, pooled across 2 RCTs (n=108: 54 per arm).
Effect 0.24 mean difference, 95% CI -3.53 to 4
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786
resveratrol — no detected effect on triglycerides
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“The pooled effect estimate revealed no effect of resveratrol on triglycerides (MD = -8.25; 95% CI [-37.25, 20.74], P = 0.58).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 108
- Population
- Women with PCOS, pooled across 2 RCTs (n=108: 54 per arm).
Effect -8.25 mean difference, 95% CI -37.25 to 20.74
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786
resveratrol — no detected effect on C-reactive protein concentration
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“The pooled effect estimate revealed no effect of resveratrol on the CRP (MD = 0.00; 95% CI [-1.31, 1.31], P = 1.00).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 148
- Dose
- 800, 1000 or 1500 mg/day oral resveratrol
- Population
- Women with polycystic ovary syndrome; 3 pooled RCTs, resveratrol vs placebo
Effect 0 mean difference, 95% CI -1.31 to 1.31
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786